Proportional hazards are a common assumption when designing confirmatory clinical trials in oncology. With the emergence of immunotherapy and novel targeted therapies, departure from the proportional hazard assumption is not rare in nowadays clinical research. Under non-proportional hazards, the hazard ratio does not have a straightforward clinical interpretation, and the log-rank test is no longer the most powerful statistical test even though it is still valid. Nevertheless, the log-rank test and the hazard ratio are still the primary analysis tools, and traditional approaches such as sample size increase are still proposed to account for the impact of non-proportional hazards. The weighed log-rank test and the test based on the restricted mean survival time (RMST) are receiving a lot of attention as a potential alternative to the log-rank test. We conduct a simulation study comparing the performance and operating characteristics of the log-rank test, the weighted log-rank test and the test based on the RMST, including a treatment effect estimation, under different non-proportional hazards patterns. Results show that, under non-proportional hazards, the hazard ratio and weighted hazard ratio have no straightforward clinical interpretation whereas the RMST ratio can be interpreted regardless of the proportional hazards assumption. In terms of power, the RMST achieves a similar performance when compared to the log-rank test.
Quantifying treatment differences in confirmatory trials under non-proportional hazards / Jimenez Moro, Jose Luis. - In: JOURNAL OF APPLIED STATISTICS. - ISSN 0266-4763. - (2020).
|Titolo:||Quantifying treatment differences in confirmatory trials under non-proportional hazards|
|Data di pubblicazione:||2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/02664763.2020.1815673|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|1908.10502.pdf||pre print autore||1. Preprint / Submitted Version||PUBBLICO - Tutti i diritti riservati||Visibile a tuttiVisualizza/Apri|
|Quantifying treatment differences in confirmatory trials under non proportional hazards.pdf||Articolo principale||2a Post-print versione editoriale / Version of Record||Non Pubblico - Accesso privato/ristretto||Administrator Richiedi una copia|